Skip to main content
. 2021 Oct 4;12:765101. doi: 10.3389/fimmu.2021.765101

Figure 1.

Figure 1

Current immunotherapies for hepatocellular carcinoma (HCC). PD1, Programmed cell death protein 1; PD-L1, Programmed cell death ligand 1; CTLA4, cytotoxic T lymphocyte antigen 4; EpCAM, epithelial cell adhesion molecule; CAR-T, Chimeric antigen receptor T cell; NK, Natural killer cell; TCR-T, T cell receptor engineered T cell; AFP, Alpha-fetoprotein; GPC3, Glypican 3; DC, dendritic cell.